Gyre Therapeutics (NASDAQ:GYRE) Trading 13.9% Higher – Should You Buy?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was up 13.9% during trading on Tuesday . The company traded as high as $11.69 and last traded at $11.77. Approximately 21,147 shares were traded during trading, a decline of 71% from the average daily volume of 72,706 shares. The stock had previously closed at $10.33.

Wall Street Analyst Weigh In

Separately, Noble Financial initiated coverage on shares of Gyre Therapeutics in a report on Tuesday. They set an “outperform” rating for the company.

Gyre Therapeutics Price Performance

The firm has a fifty day moving average of $11.24 and a 200-day moving average of $12.32.

Insider Activity at Gyre Therapeutics

In other news, President Songjiang Ma sold 2,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the transaction, the president now directly owns 2,928,467 shares in the company, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 34,054 shares of company stock worth $383,057 in the last 90 days. Corporate insiders own 19.52% of the company’s stock.

Institutional Investors Weigh In On Gyre Therapeutics

A number of institutional investors have recently added to or reduced their stakes in GYRE. Bank of America Corp DE boosted its position in shares of Gyre Therapeutics by 40.4% during the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after purchasing an additional 1,996 shares in the last quarter. Northern Trust Corp raised its stake in shares of Gyre Therapeutics by 9.1% during the 4th quarter. Northern Trust Corp now owns 103,382 shares of the company’s stock worth $1,251,000 after purchasing an additional 8,624 shares in the last quarter. Barclays PLC lifted its holdings in shares of Gyre Therapeutics by 13.5% during the 4th quarter. Barclays PLC now owns 10,543 shares of the company’s stock valued at $128,000 after buying an additional 1,255 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Gyre Therapeutics by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock valued at $49,000 after buying an additional 913 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Gyre Therapeutics by 0.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company’s stock worth $1,386,000 after acquiring an additional 918 shares in the last quarter. 23.99% of the stock is currently owned by institutional investors and hedge funds.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.